NCT01115725View on ClinicalTrials.gov

A Study to Evaluate the Ease of Use, Local Tolerance, Safety and Effectiveness of Gonal-f® (Filled-by-mass in a Prefilled Pen)

CompletedOBSERVATIONAL
Enrollment

76

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

July 31, 2008

Conditions
Infertility
Interventions
DRUG

Gonal-f® (follitropin alfa)

Gonal-f® (follitropin alfa) will be given once daily subcutaneously at a starting dose of 150-375 international unit per day (IU/day) by self-administered injection via a pen device for first 5 days. After Day 5, Gonal-f® dose will be adjusted according to the investigator's discretion until ovarian response observed.

Trial Locations (1)

151 25

EMBRYOGENESIS IVF Unit, Athens

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT01115725 - A Study to Evaluate the Ease of Use, Local Tolerance, Safety and Effectiveness of Gonal-f® (Filled-by-mass in a Prefilled Pen) | Biotech Hunter | Biotech Hunter